These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 18505062)

  • 1. Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule.
    Metro G; Fabi A; Russillo M; Papaldo P; De Laurentiis M; Ferretti G; Pellegrini D; Nuzzo C; Graziano V; Vici P; Introna M; Felici A; Cognetti F; Carlini P
    Anticancer Res; 2008; 28(2B):1245-58. PubMed ID: 18505062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
    Cinieri S; Chan A; Altundag K; Vandebroek A; Tubiana-Mathieu N; Barnadas A; Dodyk P; Lazzarelli S; Botha M; Rauch D; Villanova G; Coskun U
    Clin Breast Cancer; 2017 Apr; 17(2):91-99.e1. PubMed ID: 27756583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Metastatic breast cancer: new chemotherapy regimens with taxanes].
    Lopez M
    Clin Ter; 2005; 156(6):311-5. PubMed ID: 16463568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel/gemcitabine: salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer.
    Georgoulias VA
    Oncology (Williston Park); 2001 Feb; 15(2 Suppl 3):18-24. PubMed ID: 11252884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
    Rodgers M; Soares M; Epstein D; Yang H; Fox D; Eastwood A
    Health Technol Assess; 2011 May; 15 Suppl 1():1-12. PubMed ID: 21609648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
    Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
    Trials; 2015 Dec; 16():575. PubMed ID: 26673577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness of Taxane-Containing Regimens for Treatment of HER2-Negative Metastatic Breast Cancer: A Network Meta-analysis.
    Dong L; Zhu LN; Xie BJ; Li JB; Ding T; Jiang YF; Zhu ZN
    Pharmacotherapy; 2019 Dec; 39(12):1126-1136. PubMed ID: 31692005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine and taxanes as a new standard of care in breast cancer.
    Yardley DA
    Clin Breast Cancer; 2004 Jan; 4 Suppl 3():S107-12. PubMed ID: 14754467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the best schedule for administration of gemcitabine-taxane?
    Colomer R
    Cancer Treat Rev; 2005; 31 Suppl 4():S23-8. PubMed ID: 16360544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.
    Brugnatelli S; Danova M; De Bella MT; Vaglica M; Manuguerra G; Riccardi A; Palmeri S
    Oncology; 2002; 62(1):33-8. PubMed ID: 11810041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
    Mavroudis D; Malamos N; Alexopoulos A; Kourousis C; Agelaki S; Sarra E; Potamianou A; Kosmas C; Rigatos G; Giannakakis T; Kalbakis K; Apostolaki F; Vlachonicolis J; Kakolyris S; Samonis G; Georgoulias V
    Ann Oncol; 1999 Feb; 10(2):211-5. PubMed ID: 10093691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG).
    Frasci G; Comella P; D'Aiuto G; Thomas R; Capasso I; Elmo M; Botti G; Cortino GR; Lapenta L; De Rosa V; Vallone P; Petrillo A; Comella G
    Ann Oncol; 2000 Mar; 11(3):367-71. PubMed ID: 10811508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of gemcitabine activity in advanced breast cancer.
    Smith IE
    Semin Oncol; 2006 Jun; 33(3 Suppl 9):S19-23. PubMed ID: 16797378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
    Park YH; Im SA; Kim SB; Sohn JH; Lee KS; Chae YS; Lee KH; Kim JH; Im YH; Kim JY; Kim TY; Lee KH; Ahn JH; Kim GM; Park IH; Lee SJ; Han HS; Kim SH; Jung KH;
    Eur J Cancer; 2017 Nov; 86():385-393. PubMed ID: 29100193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer.
    Tate SC; Andre V; Enas N; Ribba B; Gueorguieva I
    Eur J Cancer; 2016 Oct; 66():95-103. PubMed ID: 27544929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine and docetaxel in metastatic breast cancer.
    Seidman AD
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 12):13-6. PubMed ID: 15685820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
    Bullock K; Blackwell K
    Oncologist; 2008 May; 13(5):515-25. PubMed ID: 18515736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
    Kontopodis E; Kentepozidis N; Christophyllakis Ch; Boukovinas I; Kalykaki A; Kalbakis K; Vamvakas L; Agelaki S; Kotsakis A; Vardakis N; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):153-60. PubMed ID: 25398698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11).
    Kim JY; Park S; Im SA; Kim SB; Sohn J; Lee KS; Chae YS; Lee KH; Kim JH; Im YH; Kim TY; Lee KH; Ahn JH; Kim GM; Park IH; Lee SJ; Han HS; Kim SH; Jung KH; Park YH;
    Cancer Commun (Lond); 2019 May; 39(1):29. PubMed ID: 31138332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taxane-based mono- or combination therapy for managing metastatic breast cancer (MBC) in routine practice: a multinational prospective observational study.
    Gümüş M; Davidson N; Bauknecht T; Soldatenkova V; Benhadji KA
    Curr Med Res Opin; 2012 Mar; 28(3):401-13. PubMed ID: 22181343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.